vs
Side-by-side financial comparison of APOGEE ENTERPRISES, INC. (APOG) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
APOGEE ENTERPRISES, INC. is the larger business by last-quarter revenue ($351.4M vs $281.3M, roughly 1.2× Guardant Health, Inc.). APOGEE ENTERPRISES, INC. runs the higher net margin — 4.7% vs -45.7%, a 50.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 1.6%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 2.9%).
Apogee Electronics is an American manufacturer of audio interfaces, analog-to-digital and digital-to-analog converters, USB & iOS microphones, and audio production software.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
APOG vs GH — Head-to-Head
Income Statement — Q4 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $351.4M | $281.3M |
| Net Profit | $16.6M | $-128.5M |
| Gross Margin | 22.4% | 64.6% |
| Operating Margin | 7.3% | -43.0% |
| Net Margin | 4.7% | -45.7% |
| Revenue YoY | 1.6% | 39.4% |
| Net Profit YoY | 568.8% | -15.8% |
| EPS (diluted) | $0.78 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $351.4M | — | ||
| Q4 25 | $348.6M | $281.3M | ||
| Q3 25 | $358.2M | $265.2M | ||
| Q2 25 | $346.6M | $232.1M | ||
| Q1 25 | $345.7M | $203.5M | ||
| Q4 24 | $341.3M | $201.8M | ||
| Q3 24 | $342.4M | $191.5M | ||
| Q2 24 | $331.5M | $177.2M |
| Q1 26 | $16.6M | — | ||
| Q4 25 | $16.5M | $-128.5M | ||
| Q3 25 | $23.6M | $-92.7M | ||
| Q2 25 | $-2.7M | $-99.9M | ||
| Q1 25 | $2.5M | $-95.2M | ||
| Q4 24 | $21.0M | $-111.0M | ||
| Q3 24 | $30.6M | $-107.8M | ||
| Q2 24 | $31.0M | $-102.6M |
| Q1 26 | 22.4% | — | ||
| Q4 25 | 23.8% | 64.6% | ||
| Q3 25 | 23.1% | 64.7% | ||
| Q2 25 | 21.7% | 65.0% | ||
| Q1 25 | 21.6% | 63.3% | ||
| Q4 24 | 26.1% | 61.6% | ||
| Q3 24 | 28.4% | 61.1% | ||
| Q2 24 | 29.8% | 59.1% |
| Q1 26 | 7.3% | — | ||
| Q4 25 | 7.1% | -43.0% | ||
| Q3 25 | 7.5% | -37.3% | ||
| Q2 25 | 2.0% | -45.9% | ||
| Q1 25 | 1.8% | -54.6% | ||
| Q4 24 | 8.4% | -62.4% | ||
| Q3 24 | 12.3% | -61.3% | ||
| Q2 24 | 12.5% | -56.8% |
| Q1 26 | 4.7% | — | ||
| Q4 25 | 4.7% | -45.7% | ||
| Q3 25 | 6.6% | -35.0% | ||
| Q2 25 | -0.8% | -43.0% | ||
| Q1 25 | 0.7% | -46.8% | ||
| Q4 24 | 6.1% | -55.0% | ||
| Q3 24 | 8.9% | -56.3% | ||
| Q2 24 | 9.4% | -57.9% |
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.77 | $-1.01 | ||
| Q3 25 | $1.10 | $-0.74 | ||
| Q2 25 | $-0.13 | $-0.80 | ||
| Q1 25 | $0.12 | $-0.77 | ||
| Q4 24 | $0.96 | $-0.90 | ||
| Q3 24 | $1.40 | $-0.88 | ||
| Q2 24 | $1.41 | $-0.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $39.5M | $378.2M |
| Total DebtLower is stronger | $232.3M | $1.5B |
| Stockholders' EquityBook value | $511.8M | $-99.3M |
| Total Assets | $1.1B | $2.0B |
| Debt / EquityLower = less leverage | 0.45× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $39.5M | — | ||
| Q4 25 | $41.3M | $378.2M | ||
| Q3 25 | $39.5M | $580.0M | ||
| Q2 25 | $32.8M | $629.1M | ||
| Q1 25 | $41.4M | $698.6M | ||
| Q4 24 | $43.9M | $525.5M | ||
| Q3 24 | $51.0M | $585.0M | ||
| Q2 24 | $30.4M | $933.7M |
| Q1 26 | $232.3M | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | $285.0M | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $511.8M | — | ||
| Q4 25 | $512.3M | $-99.3M | ||
| Q3 25 | $500.2M | $-354.5M | ||
| Q2 25 | $481.8M | $-305.5M | ||
| Q1 25 | $487.9M | $-250.8M | ||
| Q4 24 | $522.1M | $-139.6M | ||
| Q3 24 | $506.4M | $-60.1M | ||
| Q2 24 | $480.0M | $-1.6M |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $2.0B | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $917.1M | $1.5B | ||
| Q2 24 | $889.0M | $1.6B |
| Q1 26 | 0.45× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $122.5M | $-26.4M |
| Free Cash FlowOCF − Capex | — | $-54.2M |
| FCF MarginFCF / Revenue | — | -19.3% |
| Capex IntensityCapex / Revenue | 7.8% | 9.9% |
| Cash ConversionOCF / Net Profit | 7.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $122.5M | — | ||
| Q4 25 | $29.3M | $-26.4M | ||
| Q3 25 | $57.1M | $-35.4M | ||
| Q2 25 | $-19.8M | $-60.3M | ||
| Q1 25 | $30.0M | $-62.7M | ||
| Q4 24 | $31.0M | $-64.5M | ||
| Q3 24 | $58.7M | $-51.1M | ||
| Q2 24 | $5.5M | $-94.0M |
| Q1 26 | — | — | ||
| Q4 25 | $22.9M | $-54.2M | ||
| Q3 25 | $52.4M | $-45.8M | ||
| Q2 25 | $-26.9M | $-65.9M | ||
| Q1 25 | $19.1M | $-67.1M | ||
| Q4 24 | $22.0M | $-83.4M | ||
| Q3 24 | $50.2M | $-55.3M | ||
| Q2 24 | $-1.8M | $-99.1M |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | -19.3% | ||
| Q3 25 | 14.6% | -17.3% | ||
| Q2 25 | -7.8% | -28.4% | ||
| Q1 25 | 5.5% | -33.0% | ||
| Q4 24 | 6.4% | -41.3% | ||
| Q3 24 | 14.7% | -28.9% | ||
| Q2 24 | -0.5% | -55.9% |
| Q1 26 | 7.8% | — | ||
| Q4 25 | 1.9% | 9.9% | ||
| Q3 25 | 1.3% | 3.9% | ||
| Q2 25 | 2.1% | 2.4% | ||
| Q1 25 | 3.2% | 2.2% | ||
| Q4 24 | 2.6% | 9.4% | ||
| Q3 24 | 2.5% | 2.2% | ||
| Q2 24 | 2.2% | 2.9% |
| Q1 26 | 7.37× | — | ||
| Q4 25 | 1.77× | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 12.08× | — | ||
| Q4 24 | 1.48× | — | ||
| Q3 24 | 1.92× | — | ||
| Q2 24 | 0.18× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
